Wanbury is currently trading at Rs. 282.00, up by 6.60 points or 2.40% from its previous closing of Rs. 275.40 on the BSE.

The scrip opened at Rs. 275.00 and has touched a high and low of Rs. 282.00 and Rs. 274.00 respectively. So far 2989 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 330.00 on 16-May-2025 and a 52 week low of Rs. 151.10 on 01-Jul-2024.

Last one week high and low of the scrip stood at Rs. 289.80 and Rs. 265.00 respectively. The current market cap of the company is Rs. 927.13 crore.

The promoters holding in the company stood at 39.76%, while Institutions and Non-Institutions held 1.55% and 58.68% respectively.

Wanbury has successfully launched C RED, a next-generation Liposomal Iron formulation mainly designed to revolutionize anemia management in India. This novel formulation leverages liposomal technology, which ensures enhanced absorption, minimal metallic aftertaste, reduced risk of constipation, and no calcium chelation thus making it a safe and highly tolerable option for long-term use, especially in pregnant women and iron-deficient individuals.  

The product was recently launched in Northern India followed by Southern India has already garnered tremendous response from clinicians/doctors. With many healthcare professionals (doctors) expressing confidence in prescribing the product it has resulted in an impressive early sales performance. Encouraged by the initial success, Wanbury aims to scale up distribution Pan-India in the first few months of the launch.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.